A pharmacogenetics study of the human glucuronosyltransferase UGT1A4

Background UGT1A4 is primarily expressed in the liver and exhibits catalytic activities for various drugs. Amongst the few UGT1A4 polymorphisms evaluated, studies support the alteration of UGT1A4-mediated glucuronidation by a few variations including the Pro(24)Thr and Leu(48)Val variants (referred to as UGT1A4*2 and *3). Methods We therefore investigated genetic mechanisms that might contribute to interindividual variation in UGT1A4 expression and activity. The UGT1A4 gene was sequenced from - 4963 by relative to the ATG to 2000 by after the first exon in 184 unrelated Caucasians and African-Americans. Results We identified a large number of genetic variations, including 13 intronic, 39 promoter, as well as 14 exonic polymorphisms, with 10 that lead to amino-acid changes. Of the nucleotide variations found in the - 5 kb promoter region, five are located in the proximal region (first 500 bp), and positioned in putative HNF-1 and OCT-1 binding sites. Four of these variants, placed at -163, -219, -419 and -463, are in complete linkage disequilibrium with the Leu(48)Val coding region variant and with several variants in the upstream region of the promoter. Transient transfections of reference and variant promoter constructs (from position -500 to +1) in different cell lines with or without co-expression of HNF-1 and/or OCT-1 showed limited effect of these variations. Conclusion Additional functional studies on promoter variants are still required to predict their potential influence on UGT1A4 expression in vivo. Besides, several coding variants significantly modified the enzyme kinetics for tamoxifen and Z-4-hydroxytamoxifen (Val(48), Asp(50), Gln(56) Phe(176), Asn(250), Leu(276)) and are expected to have a potential in vivo effect. Pharmacogenetics and Genomics 19:945-954 (C) 2009 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.